NURIX THERAPEUTICS INC's ticker is NRIX and the CUSIP is 67080M103. A total of 103 filers reported holding NURIX THERAPEUTICS INC in Q1 2021. The put-call ratio across all filers is - and the average weighting 0.9%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $154,017 | -2.1% | 19,595 | +24.4% | 0.00% | – |
| Q2 2023 | $157,382 | -37.6% | 15,754 | -44.6% | 0.00% | – |
| Q1 2023 | $252,308 | +16.4% | 28,413 | +43.9% | 0.00% | – |
| Q4 2022 | $216,811 | -14.3% | 19,746 | +1.6% | 0.00% | – |
| Q3 2022 | $253,000 | -4.9% | 19,436 | -7.3% | 0.00% | – |
| Q2 2022 | $266,000 | +5.6% | 20,963 | +16.8% | 0.00% | – |
| Q1 2022 | $252,000 | -56.4% | 17,952 | -10.1% | 0.00% | – |
| Q4 2021 | $578,000 | 0.0% | 19,970 | +3.5% | 0.00% | – |
| Q3 2021 | $578,000 | +9.7% | 19,293 | -2.9% | 0.00% | – |
| Q2 2021 | $527,000 | +7.6% | 19,875 | +26.2% | 0.00% | – |
| Q1 2021 | $490,000 | +14.2% | 15,745 | +20.8% | 0.00% | – |
| Q4 2020 | $429,000 | +107.2% | 13,036 | +119.8% | 0.00% | – |
| Q3 2020 | $207,000 | – | 5,931 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Bain Capital Life Sciences Investors, LLC | 1,822,883 | $14,327,860 | 1.60% |
| DAFNA Capital Management LLC | 556,695 | $4,375,623 | 1.36% |
| Redmile Group, LLC | 2,848,827 | $22,391,780 | 1.06% |
| Deep Track Capital, LP | 2,997,830 | $23,562,944 | 0.91% |
| WestHill Financial Advisors, Inc. | 283,333 | $2,226,997 | 0.65% |
| Soleus Capital Management, L.P. | 814,000 | $6,398,040 | 0.59% |
| Affinity Asset Advisors, LLC | 250,000 | $1,965,000 | 0.55% |
| Boxer Capital, LLC | 1,224,892 | $9,627,651 | 0.51% |
| AtonRa Partners | 24,227 | $190,424 | 0.40% |
| WASATCH ADVISORS LP | 3,564,616 | $28,017,882 | 0.18% |